Royalty Pharma PLC (NASDAQ:RPRX) Plans Quarterly Dividend of $0.23

Royalty Pharma PLC (NASDAQ:RPRX) announced a quarterly dividend on Friday, July 17th. Stockholders of record on Friday, August 14th will be given a dividend of 0.235 per share by the biopharmaceutical company on Thursday, September 10th. This represents a c) dividend on an annualized basis and a dividend yield of 1.6%. The ex-dividend date is Friday, August 14th.

Royalty Pharma has raised its dividend by an average of 0.2%annually over the last three years and has increased its dividend every year for the last 5 years. Royalty Pharma has a dividend payout ratio of 18.7% meaning its dividend is sufficiently covered by earnings. Equities research analysts expect Royalty Pharma to earn $5.53 per share next year, which means the company should continue to be able to cover its $0.94 annual dividend with an expected future payout ratio of 17.0%.

Royalty Pharma Stock Up 2.0%

NASDAQ:RPRX traded up $1.17 during mid-day trading on Wednesday, hitting $58.96. 151,919 shares of the company’s stock traded hands, compared to its average volume of 3,534,631. The company has a fifty day moving average of $56.60 and a 200 day moving average of $50.80. The company has a debt-to-equity ratio of 0.88, a quick ratio of 2.80 and a current ratio of 2.80. Royalty Pharma has a twelve month low of $34.08 and a twelve month high of $60.44. The company has a market capitalization of $33.95 billion, a P/E ratio of 40.74, a P/E/G ratio of 1.35 and a beta of 0.43.

Royalty Pharma (NASDAQ:RPRX) last issued its quarterly earnings results on Wednesday, August 5th. The biopharmaceutical company reported $1.32 earnings per share for the quarter, topping the consensus estimate of $1.27 by $0.05. Royalty Pharma had a return on equity of 30.01% and a net margin of 32.14%.The business had revenue of $674.14 million during the quarter, compared to the consensus estimate of $758.93 million. On average, analysts forecast that Royalty Pharma will post 5.3 EPS for the current year.

About Royalty Pharma

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company’s transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.